USFDA completes PADE inspection of Jubilant Pharmova’s arm

22 Sep 2025 Evaluate

United States Food and Drug Administration (USFDA) has completed Post-marketing Adverse Drug Experience (PADE) inspection at Jubilant Pharmova’s stepdown wholly owned subsidiary -- Jubilant Cadista Pharmaceuticals Inc, USA. The inspection closed with no observations. 

The above inspection concluded with zero observations, reaffirming Jubilant commitment to maintaining the highest standards of quality, safety, and compliance.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

1049.40 -24.90 (-2.32%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×